Approval · Notice of Compliance 835 · 2002
TERAZOSIN: Notice of Compliance 835
Issued September 9, 2002
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 835
- Date
- September 9, 2002
- Company
- Pharmel Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- New manufacturer and product name
- Therapeutic class
- Antihypertensive agent/symptomatic treatment of benign prostatic hyperplasia
- Canadian reference product
- HYTRIN (Abbott Laboratories Co.)
Products in this notice
Medicinal ingredients
- TERAZOSIN HCL 1 MG per TAB
- TERAZOSIN HCL 2 MG per TAB
- TERAZOSIN HCL 5 MG per TAB
- TERAZOSIN HCL 10 MG per TAB